Commentary: Reproductive function in human immunodeficiency virus infection

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 6, 2001, Pages 2338-2343

  Lo, Joan C ^a   Schambelan, Morris ^b  

^a SAN FRANCISCO GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYTOCHROME P450 3A4; ESTRATEST; GESTAGEN; INDINAVIR; METHYLTESTOSTERONE; NELFINAVIR; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SEX HORMONE; SILDENAFIL; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE;

DISEASE ASSOCIATION; ETHICS; FERTILITY; GYNECOMASTIA; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; LIVER DYSFUNCTION; OVARY FUNCTION; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SEXUAL DYSFUNCTION; TESTIS FUNCTION; VIRUS TRANSMISSION; FEMALE; MALE; OVARY; OVARY DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; TESTIS;

HUMAN IMMUNODEFICIENCY VIRUS;

FEMALE; FERTILITY; GONADAL STEROID HORMONES; HIV INFECTIONS; HUMANS; HYPOGONADISM; MALE; OVARIAN DISEASES; OVARY; REPRODUCTION; REPRODUCTIVE MEDICINE; TESTIS;

EID: 0035380763     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.6.2338     Document Type: Review

References (104)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Histopathology of testis in acquired immune deficiency syndrome
3. Testicular atrophy in AIDS: A study of 57 autopsy cases
4. HIV in testis: Quantitative histology and HIV localization in germ cells
5. Changing testicular histology in AIDS: Its implication for sexual transmission of HIV
6. Endocrine disorders in men infected with human immunodeficiency virus
7. Evidence for changes in adrenal and testicular steroids during HIV infection
8. Evidence of endocrine involvement early in the course of human immunodeficiency virus infection
9. Changes in systemic gonadal and adrenal steroids in asymptomatic human immunodeficiency virus-infected men: Relationship with the CD4 cell counts
10. Alterations in the concentrations and binding properties of sex steroid binding protein and corticosteroid-binding globulin in HIV+ patients
11. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting
12. Changes in the hypothalamic-pituitary-gonadal axis in human immunodeficiency virus-infected homosexual men
13. Testicular dysfunction in human immunodeficiency virus-infected men
14. Reproductive effects of nontesticular illness
15. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome
16. Serum hormones in men with human immunodeficiency virus-associated wasting
17. Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS
18. Testosterone, illness progression, and megestrol use in HIV-positive men
19. The use of ketoconazole as an inhibitor of steroid production
20. Drug abuse and reproduction
21. Toxoplasmosis presenting as panhypopituitarism in a patient with the acquired immune deficiency syndrome
22. Hypopituitarism associated with a hypothalamic CMV infection in a patient with AIDS
23. Report of gynecomastia in five male patients during antiretroviral therapy for HIV infection
24. Gynaecomastia in a male patient during protease inhibitor treatment for acute HIV disease
25. Gynecomastia during indinavir antiretroviral therapy in HIV infection
26. HIV protease inhibitors, saquinavir, indinavir and ritonavir: Inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes
27. Gynecomastia with stavudine treatment in an HIV-positive patient
28. Gynaecomastia associated with saquinavir therapy
29. Testosterone replacement treatment options for HIV-infected men
30. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men
31. Androgel
32. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: Application of gel at one site versus four sites: A General Clinical Research Center study
33. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial
34. Can androgen therapy replete lean body mass and improve muscle function in wasting associated with human immunodeficiency virus infection?
35. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels
36. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial
37. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: A randomized controlled trial
38. Sexual risk behavior, sexual functioning, and HIV-disease progression in gay men
39. Psychosexual problems in people with HIV infection: Controlled study of gay men and men with haemophilia
40. Sexual dysfunction in advanced HIV disease
41. Sexual functioning in ambulatory men with HIV/AIDS
42. Sexual dysfunction with protease inhibitors
43. Sexual dysfunction with protease inhibitors
44. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients
45. Fertility parameters in men infected with human immunodeficiency virus
46. The effects of disease progression and zidovudine therapy on semen quality in human immunodeficiency virus type 1 seropositive men
47. Semen analysis in human immunodeficiency virus infection
48. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy
49. HIV and germinal cells: How close an association?
50. Insemination of HIV-negative women with processed semen of HIV-positive partners
51. Reproductive counselling for HIV-discordant couples
52. Human immunodeficiency virus type 1-serodiscordant couples can bear healthy children after undergoing intrauterine insemination
53. Evaluation of sperm washing as a potential method of reducing HIV transmission in HIV-discordant couples wishing to have children
54. Pregnancy following intracytoplasmic sperm injection from an HIV-1-seropositive man
55. Premenopausal cytomegalovirus oophoritis in a patient with AIDS
56. Human immunodeficiency virus type I infection of cells and tissues from the upper and lower human female reproductive tract
57. Cervical and vaginal shedding of human immunodeficiency virus type 1-infected cells throughout the menstrual cycle
58. Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina
59. Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome
60. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting
61. Menstrual symptoms in women infected by the human immunodeficiency virus
62. Characteristics of menstruation in women infected with human immunodeficiency virus
63. Effect of HIV infection on menstrual cycle length
64. Hormonal levels among HIV-1-seropositive women compared with high-risk HIV-seronegative women during the menstrual cycle
65. Hypertrophy of the breasts in a patient treated with indinavir
66. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
67. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART)
68. HIV protease inhibitors, the lipodystrophy syndrome and polycystic ovary syndrome - Is there a link?
69. Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome
70. Hypermenorrhea associated with ritonavir
71. Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors
72. Women and HIV - Revisited ten years on
73. Perimenopausal symptomatology among HIV-infected women at least 40 years of age
74. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
75. The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and in human immunodeficiency virus-infected women
76. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: A pilot study
77. Pharmacokinetics of a novel testosterone matrix transdermal system in healthy, premenopausal women and women infected with the human immunodeficiency virus
78. The effect of HIV diagnosis on reproductive experience
79. Fertility and reproductive choice in women with HIV-1 infection
80. Pregnancy and contraception in a French cohort of HIV-infected women
81. Sexual, contraceptive, and drug use behaviors of women with HIV and those at high risk for infection: Results from the Women's Interagency HIV Study
82. Gynecology and family planning care for the woman infected with HIV
83. Excess intrauterine fetal demise associated with maternal human immunodeficiency virus infection
84. Early spontaneous abortions and fetal thymic abnormalities in maternal-to-fetal HIV infection
85. Pregnancy outcomes among mothers infected with human immunodeficiency virus and uninfected control subjects
86. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
87. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
88. Mother-to-child transmission of the human immunodeficiency virus
89. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine
90. HIV-1 transmission through breast-milk: Appraisal of risk according to duration of feeding
91. Reproductive decision-making and determinants of contraceptive use in HIV-infected women
92. Infertility among human immunodeficiency virus-positive women: Incidence and treatment dilemmas
93. The impact of HIV on a fertility problems clinic
94. Attitudes towards routine human immunodeficiency virus (HIV) screening and fertility treatment in HIV positive patients - A UK survey
95. HIV infection in women: Immunological markers and the influence of pregnancy
96. Does pregnancy influence the course of HIV infection? Evidence from two large Swiss cohort studies
97. Pregnancy and progression to AIDS: Results of the French prospective cohorts
98. Antiretroviral therapy for pregnant women
99. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study
100. Multicenter review of protease inhibitors in 89 pregnancies
101. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
102. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: Absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts